| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8840924 | NEOS THERAPS INC | Compositions and methods of making rapidly dissolving ionically masked formulations |
Jun, 2026
(2 years from now) | |
| US9089496 | NEOS THERAPS INC | Compositions comprising methylphenidate complexed with ion-exchange resin particles |
Jun, 2032
(8 years from now) | |
| US9072680 | NEOS THERAPS INC | Compositions comprising methylphenidate complexed with ion-exchange resin particles |
Jun, 2032
(8 years from now) | |
| US11166947 | NEOS THERAPS INC | Effective dosing of a child for the treatment of ADHD with methylphenidate |
Jan, 2038
(13 years from now) | |
Cotempla Xr-Odt is owned by Neos Theraps Inc.
Cotempla Xr-Odt contains Methylphenidate.
Cotempla Xr-Odt has a total of 4 drug patents out of which 0 drug patents have expired.
Cotempla Xr-Odt was authorised for market use on 19 June, 2017.
Cotempla Xr-Odt is available in tablet, orally disintegrating, extended release;oral dosage forms.
Cotempla Xr-Odt can be used as treatment of attention deficit hyperactivity disorder (adhd) in pediatric patients.
The generics of Cotempla Xr-Odt are possible to be released after 25 January, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 19, 2020 |
Drugs and Companies using METHYLPHENIDATE ingredient
Market Authorisation Date: 19 June, 2017
Treatment: Treatment of attention deficit hyperactivity disorder (adhd) in pediatric patients
Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL
COTEMPLA XR-ODT family patents
